Clinical consequences of hospital variation in use of oral anticoagulant therapy after first-time admission for atrial fibrillation

Journal of Internal Medicine

Volumn 265, Issue 3, 2009, Pages 335-344

  Hansen, M L ^a   Gadsboll N ^b   Rasmussen, S ^c   Gislason, G H ^d   Folke, F ^a   Andersen, S S ^a   Schramm, T K ^a   Sorensen R ^a   Fosbol E L ^a   Abildstrom S Z ^e   Madsen, M ^f   Poulsen, H E ^g   Kober L ^d   Torp Pedersen, C ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Department of Medicine   (Denmark)

^c National Institute of Public

^d Mental Health Center Glostrup   (Denmark)

^e GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

^g Rigshospitalet   (Denmark)

Author keywords

Atrial fibrillation; Epidemiology; Hospital quality measurement; Oral anticoagulant therapy; Thromboembolism

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DILTIAZEM; FLECAINIDE; PHENPROCOUMON; PROPAFENONE; SOTALOL; VERAPAMIL; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DRUG UTILIZATION; FEMALE; HEART ATRIUM FIBRILLATION; HEMORRHAGIC STROKE; HOSPITAL CARE; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OBSERVATIONAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; STROKE; THROMBOEMBOLISM;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; DENMARK; FEMALE; HOSPITALS; HUMANS; MALE; MIDDLE AGED; PATIENT READMISSION; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; STROKE; THROMBOEMBOLISM;

EID: 60449087296     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2008.02061.x     Document Type: Article

References (29)

1. Fuster V, Ryden LE, Asinger RW et al. ACC/AHA/ESC Guidelines for the management of patients with atrial fibrillation: executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation) Developed in Collaboration with the North American Society of Pacing and Electrophysiology. Circulation 2001 104 : 2118 50.
2. Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). J Am Coll Cardiol 2006 48 : 854 906.
3. Nieuwlaat R, Capucci A, Camm AJ et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005 26 : 2422 34.
4. Lock Hansen M, Gadsboll N, Gislason GH et al. Atrial fibrillation pharmacotherapy after hospital discharge between 1995 and 2004: a shift towards beta-blockers. Europace 2008 10 : 395 402.
5. Gaist D, Andersen M, Aarup AL, Hallas J, Gram LF. Use of sumatriptan in Denmark in 1994-5: an epidemiological analysis of nationwide prescription data. Br J Clin Pharmacol 1997 43 : 429 33.
6. Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. Dan Med Bull 1997 44 : 445 8.
7. Gislason GH, Rasmussen JN, Abildstrom SZ et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 2006 27 : 1153 8.
8. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001 285 : 2864 70.
9. Krarup LH, Boysen G, Janjua H, Prescott E, Truelsen T. Validity of stroke diagnoses in a National Register of Patients. Neuroepidemiology 2007 28 : 150 4.
10. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999 131 : 492 501.
11. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991 18 : 349 55.
12. Ezekowitz MD, Bridgers SL, James KE et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992 327 : 1406 12.
13. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med 1990 323 : 1505 11.
14. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991 84 : 527 39.
15. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989 1 : 175 9.
16. Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 1999 131 : 927 34.
17. Majeed A, Moser K, Carroll K. Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994-1998: analysis of data from the general practice research database. Heart 2001 86 : 284 8.
18. White RH, McBurnie MA, Manolio T et al. Oral anticoagulation in patients with atrial fibrillation: adherence with guidelines in an elderly cohort. Am J Med 1999 106 : 165 71.
19. Sudlow M, Thomson R, Thwaites B, Rodgers H, Kenny RA. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet 1998 352 : 1167 71.
20. Fang MC, Stafford RS, Ruskin JN, Singer DE. National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch Intern Med 2004 164 : 55 60.
21. Humphries KH, Kerr CR, Connolly SJ et al. New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. Circulation 2001 103 : 2365 70.
22. Cohen N, Almoznino-Sarafian D, Alon I et al. Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission. Stroke 2000 31 : 1217 22.
23. Waldo AL, Becker RC, Tapson VF, Colgan KJ. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol 2005 46 : 1729 36.
24. Nieuwlaat R, Capucci A, Lip GY et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2006 27 : 3018 26.
25. Choudhry NK, Soumerai SB, Normand SL, Ross-Degnan D, Laupacis A, Anderson GM. Warfarin prescribing in atrial fibrillation: the impact of physician, patient, and hospital characteristics. Am J Med 2006 119 : 607 15.
26. Munschauer FE, Priore RL, Hens M, Castilone A. Thromboembolism prophylaxis in chronic atrial fibrillation. Practice patterns in community and tertiary-care hospitals. Stroke 1997 28 : 72 6.
27. Gislason GH, Rasmussen JN, Abildstrom SZ et al. Persistent use of evidence-based pharmacotherapy in heart failure is associated with improved outcomes. Circulation 2007 116 : 737 44.
28. Frost L, Vukelic Andersen L, Vestergaard P, Husted S, Mortensen LS. Trends in risk of stroke in patients with a hospital diagnosis of nonvalvular atrial fibrillation: National Cohort Study in Denmark, 1980-2002. Neuroepidemiology 2006 26 : 212 9.
29. Fang MC, Chang Y, Hylek EM et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004 141 : 745 52.